LoginRegister

    Brands in India to be included in review for consumer health business: Pfizer

    Written by Ruby Khatun Khatun   |  

    New Delhi: Drug firm Pfizer said Gelusil, Becosules and Corex brands in India will be included in the global strategic review of the consumer healthcare business of Pfizer Inc, in addition to Anacin and Anne French.


    Pfizer Inc had announced on October 10, 2017, that it is reviewing strategic alternatives for its consumer healthcare business, Pfizer Ltd said in a statement.


    The review will consider a range of options, including a full or partial separation of the consumer healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business, it added.



    As part of this global review, certain products from across the Pfizer enterprise have also been identified as being good fits with the suite of products within Pfizer Consumer Healthcare, it said.


    "Consequently, in India, the brands Gelusil, Becosules, and Corex will be included in the global strategic review of the consumer healthcare business, in addition to consumer healthcare brands Anacin and Anne French," it added.


    Regardless of the outcomes of this review, Pfizer India will continue to focus on and build upon its core prescription portfolio through current and future investments, the company said.


    "The company will build on a strategy of strengthening and enhancing its presence in core therapy areas including Sterile Injectables, anti-infectives, vaccines, women's health, metabolic disease and cardiovascular risk, pain management, and oncology," it added.








    "Over time, Pfizer will look to bringing several additional global Pfizer brands to India and globalize the India portfolio," it said.


    Until the outcome of this review of strategic alternatives is determined, Gelusil, Becosules, and Corex will continue to be manufactured and marketed by Pfizer as they are today, it added.






    AnacinAnne Frenchanti infectivesBecosulesBrandscardiovascular riskconsumer healthcare businessCorexGelusilglobal strategic reviewIndiametabolic diseasePfizerSterile Injectablesvaccines
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X